REMINDER: Heat Biologics to Host Planned Investor and Media Livestream Event on Tuesday, April 19th at 10:30 AM ET to Discuss Latest Developments
DURHAM, N.C., April 18, 2022 – Heat Biologics (NYSE American: HTBX) is hosting a livestream event on April 19, 2022, at 10:30 AM ET to discuss recent developments.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
DURHAM, N.C., April 18, 2022 – Heat Biologics (NYSE American: HTBX) is hosting a livestream event on April 19, 2022, at 10:30 AM ET to discuss recent developments. Investors can join the event at this link. Heat Biologics focuses on developing innovative therapies and vaccines to modulate the immune system, featuring its gp96 platform. Ongoing projects include HS-110 in Phase 2 trials, and other immunomodulatory products in various development stages. For additional details, visit www.heatbio.com.
Details
News Market Reaction – HTBX
The recorded move for HTBX in the trading session of this news was -11.50%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, reminds investors that it will host an investor and media livestream event on Tuesday, April 19, 2022 at 10:30 AM Eastern Time to discuss the latest developments. The event will be broadcast at: https://vimeo.com/event/2027558/fc6de52c31
About Heat Biologics, Inc.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies and vaccines to modulate the immune system. Heat’s gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in a Phase 2 trial, various infectious disease/biological threat programs in preclinical development and a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
For more information, please visit: www.heatbio.com, and also follow us on Twitter.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
investorrelations@heatbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.